236 related articles for article (PubMed ID: 22826396)
21. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
[TBL] [Abstract][Full Text] [Related]
23. Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion.
Duan F; Wang EQ; Lam MG; Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Kuo WT; Hofmann LV; Sze DY
Radiology; 2016 Feb; 278(2):612-21. PubMed ID: 26334787
[TBL] [Abstract][Full Text] [Related]
24. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
[TBL] [Abstract][Full Text] [Related]
25. Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma.
Park KH; Kwon SH; Lee YS; Jeong SW; Jang JY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim YJ
Clin Mol Hepatol; 2015 Jun; 21(2):158-64. PubMed ID: 26157753
[TBL] [Abstract][Full Text] [Related]
26. Safety margins of hepatocellular carcinoma demonstrated by 3-dimensional fused images of computed tomographic hepatic arteriography/unenhanced computed tomography: prognostic significance in patients who underwent transcatheter arterial chemoembolization.
Tajima T; Nishie A; Asayama Y; Ishigami K; Ushijima Y; Kakihara D; Honda H
J Comput Assist Tomogr; 2010; 34(5):712-9. PubMed ID: 20861774
[TBL] [Abstract][Full Text] [Related]
27. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?
Loffroy R; Lin M; Yenokyan G; Rao PP; Bhagat N; Noordhoek N; Radaelli A; Blijd J; Liapi E; Geschwind JF
Radiology; 2013 Feb; 266(2):636-48. PubMed ID: 23143027
[TBL] [Abstract][Full Text] [Related]
28. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
Varela M; Real MI; Burrel M; Forner A; Sala M; Brunet M; Ayuso C; Castells L; Montañá X; Llovet JM; Bruix J
J Hepatol; 2007 Mar; 46(3):474-81. PubMed ID: 17239480
[TBL] [Abstract][Full Text] [Related]
29. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study.
Shaw CM; Eisenbrey JR; Lyshchik A; O'Kane PL; Merton DA; Machado P; Pino L; Brown DB; Forsberg F
J Ultrasound Med; 2015 May; 34(5):859-67. PubMed ID: 25911704
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): preliminary data.
Uller W; Wiggermann P; Gössmann H; Klebl F; Salzberger B; Stroszczynski C; Jung EM
Clin Hemorheol Microcirc; 2011; 49(1-4):55-66. PubMed ID: 22214678
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE).
Nakano MM; Yamamoto A; Nishida N; Hamuro M; Hamamoto S; Jogo A; Sohgawa E; Kageyama K; Minami T; Miki Y
Jpn J Radiol; 2019 Jul; 37(7):543-548. PubMed ID: 31055710
[TBL] [Abstract][Full Text] [Related]
32. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Huang K; Zhou Q; Wang R; Cheng D; Ma Y
J Gastroenterol Hepatol; 2014 May; 29(5):920-5. PubMed ID: 24224722
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
34. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center.
Vogl TJ; Trapp M; Schroeder H; Mack M; Schuster A; Schmitt J; Neuhaus P; Felix R
Radiology; 2000 Feb; 214(2):349-57. PubMed ID: 10671580
[TBL] [Abstract][Full Text] [Related]
35. Parametric response mapping of dynamic CT as an imaging biomarker to distinguish viability of hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Choi SJ; Kim J; Seo J; Kim HS; Lee JM; Park H
Abdom Imaging; 2014 Jun; 39(3):518-25. PubMed ID: 24519566
[TBL] [Abstract][Full Text] [Related]
36. [Transcatheter arterial chemoembolization with doxorubicin eluting beads in the treatment of hepatocellular carcinoma].
Sousa PF; Preto AS; Leão D; Madureira AM; Paquete J; Costa-Maia J; Vilares-Morgado P
Acta Med Port; 2011; 24(1):29-36. PubMed ID: 21672439
[TBL] [Abstract][Full Text] [Related]
37. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.
Bargellini I; Vignali C; Cioni R; Petruzzi P; Cicorelli A; Campani D; De Simone P; Filipponi F; Bartolozzi C
Radiology; 2010 Apr; 255(1):289-300. PubMed ID: 20308465
[TBL] [Abstract][Full Text] [Related]
38. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
[TBL] [Abstract][Full Text] [Related]
39. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Pinter M; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Stauber R; Grünberger B; Müller C; Kölblinger C; Peck-Radosavljevic M; Sieghart W
Radiology; 2012 May; 263(2):590-9. PubMed ID: 22438359
[TBL] [Abstract][Full Text] [Related]
40. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size.
Lee YK; Jung KS; Kim DY; Choi JY; Kim BK; Kim SU; Park JY; Ahn SH; Han KH; Kim GM; Kim MD; Park SI; Won JY; Lee DY
J Gastroenterol Hepatol; 2017 Feb; 32(2):487-496. PubMed ID: 27503585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
